期刊文献+

半乳糖凝集素3表达在良恶性甲状腺肿瘤鉴别中的意义 被引量:13

Significance of galectin-3 expression in differentiating benign and malignant thyroid neoplasms
原文传递
导出
摘要 目的 探讨半乳糖凝集素3表达对鉴别良恶性甲状腺肿瘤的临床价值。方法 采用免疫化学染色法(SP法)观察72例手术切除的甲状腺肿瘤标本半乳糖凝集素3的表达。结果 半乳糖凝集素3在恶性肿瘤的细针抽吸(FNA)细胞涂片与组织切片中均高水平表达,在良性肿瘤中不表达或低表达。良性与恶性甲状腺肿瘤在FNA细胞涂片或组织切片中半乳糖凝集素3的表达差异有统计学意义(χ2 =43. 73,χ2 =48. 16,均P<0. 01)。相同性质的甲状腺肿瘤FNA细胞涂片与组织切片的半乳糖凝集素3表达一致,两者之间差异无统计学意义(χ2 =0. 04,χ2 =0. 19,均P>0. 05)。结论 半乳糖凝集素3在良恶性甲状腺肿瘤中表达不同,恶性肿瘤中表达显著增高,是鉴别良恶性甲状腺肿瘤可靠的分子标记物,可用于FNA涂片标本及组织标本检测。 Objective To investigate the clinical value of galectin-3 expression on fine needle aspiration (FNA) smearsandtissueslicesof thyroid tumors in distinguishing benign from malignant tumors. Methods Galectin-3 expression on FNA smears and tissue slices of thyroid tumors from 72 thyroidectomy specimens was detected by immunochemical method (SP method). Results Galectin-3 expression was high on FNA smears and tissue slices of malignant thyroid tumors, whereas there was no or low expression of galectin-3 on FNA smears and tissue slices of benign thyroid tumors. The difference of positive rates of galectin-3 expression between malignant and benign thyroid tumors was significant on both FNA smears and tissue slices (χ 2=43.73 and χ 2=48.16, respectively, both P<0.01). There was no significant difference between immunocytochemical methods on FNA smears and immunohistochemical methods on tissue slices in the same benign or malignant thyroid neoplasms (χ 2=0.04, χ 2=0.19, both P>0.05). Conclusion Galectin-3 expression is different between benign and malignant tumors. Galectin-3 expression level is higher in FNA smears and tissue slices of malignant thyroid neoplasms than that of benign ones, suggesting that galectin-3 is a reliable molecular marker in distinguishing benign from malignant thyroid tumors. Galectin-3 expression with immunochemical method may be used in diagnosing benign or malignant thyroid tumors.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2005年第2期121-125,共5页 Chinese Journal of Endocrinology and Metabolism
关键词 半乳糖凝集素3 基因表达 甲状腺肿瘤 鉴别诊断 细胞涂片 Thyroid neoplasms Biological markers Galectin-3 Biopsy, fine-needle
  • 相关文献

参考文献15

  • 1白耀.甲状腺恶性肿瘤诊断和治疗的热点讨论[J].中华内分泌代谢杂志,2004,20(4):283-286. 被引量:19
  • 2Orlandi F, Saggiorato E, Pivano G, et al, Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res, 1998,58:3015-3020.
  • 3Barondes SH, Cooper DN, Gitt MA, et al. Galectins, Structure and function of a large family of animal lectins. J Biol Chem, 1994,269:20807-20810.
  • 4Yoshii T, Inohara H, Takenaka Y, at el. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol, 2001,18:787-792.
  • 5Perillo NL, Marcus ME, Baum LG. Galectins: versatik modulators of cell adhesion, cell proliferation, and cell death. J Mol Med, 1998,76:402-412.
  • 6Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol, 2000,156:899-909.
  • 7Akahani S, Nangia-Makker P, Inohara H, et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res, 1997,57:5272-5276.
  • 8Xu XC, NI Naggar AK, Lotan R, et al. Differential expression of galectin-1 and galectin-3 in thyoid tumors: Potential diagnostic implications. Am J Pathol, 1995,147:815-822.
  • 9Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer, 1999,85:2475-2484.
  • 10Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well-differentiated thyroid cancirnoma, is expressed in thyroid nodules with cytological atypia. Histopathology, 2002,40:80-87.

二级参考文献27

  • 1牛恕淼 何惠玲 高慧 等.细针吸取活检诊断自身免疫性甲状炎和毒性甲状腺肿[J].中华病理学杂志,1987,16:171-173.
  • 2施秉银.内分泌及风湿病临床基本操作[A].马爱群主编.内科临床基本操作[C].北京:人民卫生出版社,2003.335-337.
  • 3Koh JM, Kim ES, Ryu JS, et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol, 58:421-427.
  • 4Pellegriti G, Scollo C, Regalbuto C. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol, 58:556-561.
  • 5Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med, 2003,253:616-626.
  • 6Giammarile F, Hafdi Z, Bournaud C, et al. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable r
  • 7van Tol KM, Jager PL, de Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol, 2003,148:589-596.
  • 8Frasoldati A, Pesenti M, Gallo M. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer, 2003,97:90-96.
  • 9Torlontano M, Crocetti U, D′Aloiso L, et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol, 2003,148:19-24.
  • 10el Hag IA, Chiedozi LC, al Reyees FA. Fine needle aspiration cytology of head and neck masses. Seven years′ experience in a secondary care hospital. Acta Cytol, 2003,47:387-392.

共引文献155

同被引文献129

引证文献13

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部